
Manraj Singh Sra
@manrajsra
Research Fellow in Hematology @MayoClinic, MBBS @AIIMS_NewDelhi. Views mine.
ID: 1241045318428266497
20-03-2020 16:54:04
74 Tweet
416 Followers
1,1K Following

It was great to discuss FAQs regarding ICMR STS and my project. Hope it's useful for med students planning to start research. Shout out to Dr. Amulya Gupta for this amazing initiative 🙌



India provides a unique habitat in which practitioners of alternative medicinal traditions can survive. A general lack of awareness, together with desperation brought on by the pandemic, prompt people to fall prey to false remedies. | Dr. Amulya Gupta science.thewire.in/health/covid-1…

Do check out our article on COVID-19 and co-infection with seasonal diseases Dr. Amulya Gupta maladyscience.com/2020/10/16/cov…






Our analysis of the retracted COVID-19 papers shows that pre-prints are retracted significantly faster than peer-reviewed articles. Retraction Watch medrxiv.org/content/10.110…



When intelligent people succumb to ideology, their intellect ceases to guard against wishful thinking and instead begins to fortify it, causing them to inadvertently mastermind their own delusion, and to very cleverly become stupid. My new essay. gurwinder.substack.com/p/why-smart-pe…

Addition of olanzapine as a 4th line anti-emetic is cost-effective for children and adolescents receiving HEC in 🇮🇳🇧🇩🇮🇩🇬🇧🇺🇸 Read our latest paper in BMJ SPCare spcare.bmj.com/content/early/… Shuvadeep Ganguly Ramavath Dev Sameer Bakhshi

Are abemaciclib and ribociclib cost-effective for early breast cancer in India? Our study finds they are not. Prices must drop by at least 78.61% for abemaciclib and 87.19% for ribociclib to be cost-effective. Shuvadeep Ganguly JCO Global Oncology bit.ly/3Wdo4RY


